ATMstockresearch

ATM Stock Research - Reiterates BUY at $282.54

Alış
ASX:CSL   CSL LIMITED
ATM Stock Research
CSL Limited – Technical Analysis Summary-
CSL is a global biotechnology company that was listed on ASX at $2.30 per share back in June 1994. ATM stock research initially recommended the stock at $91.87 in 2016. The stock was at its peak on 20th February this year at $342.28. The Covid 19 Sell-off reversed the stock to $242.64 levels in March. Later the market wide recovery in April was not long lasting for CSL. Moreover, the recent trading update was not as expected and the investors took to profit taking, creating an opportunity for others. We believe given the strong fundamentals and being a quality healthcare company, the stock is still not fully priced and this makes it an attractive BUY at $282.54 at the time of report writing. There are short term resistances at $294 and then at $305. Once both of these resistance levels are broken, we see that CSL will march towards @ $3.21 in the medium term. ATM reiterates a Buy on CSL for all our clients and readers at the current levels.

atmstrategy.co.nz/member/stock/CSL.AX
Feragatname

Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, işlem veya diğer türden tavsiye veya tavsiyeler anlamına gelmez ve teşkil etmez. Kullanım Şartları'nda daha fazlasını okuyun.